A5052856218- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Acute Myeloid Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Cancer-related gene regulation
- RNA modifications and cancer
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Genomics and Chromatin Dynamics
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Genetic Syndromes and Imprinting
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Viral-associated cancers and disorders
- Vascular Tumors and Angiosarcomas
- Single-cell and spatial transcriptomics
- RNA Research and Splicing
- Galectins and Cancer Biology
- Hemoglobinopathies and Related Disorders
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Hematopoietic Stem Cell Transplantation
Weill Cornell Medicine
2020-2024
Cornell University
2020-2024
NYU Langone Health
2021
La Ligue Contre le Cancer
2015-2020
Inserm
2012-2020
Institut Gustave Roussy
2012-2020
Université Paris-Sud
2012-2018
Université Paris-Saclay
2013-2018
Contrôle transcriptionnel et épigénétique de l’hématopoïèse maligne
2018
Institut National de Recherche en Santé Publique
2014-2015
Appropriate cancer care requires a thorough understanding of the natural history disease, including cell origin, pattern clonal evolution, and functional consequences mutations. Using deep sequencing flow-sorted populations from patients with chronic lymphocytic leukemia (CLL), we established presence acquired mutations in multipotent hematopoietic progenitors. Mutations affected known lymphoid oncogenes, BRAF, NOTCH1, SF3B1. NFKBIE EGR2 were observed at unexpectedly high frequencies, 10.7%...
Purpose Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence IDH1/2 mutations at diagnosis provide a marker minimal residual disease (MRD). Patients Methods Serum samples from 82 patients de novo AML (IDH1/2 mutated, n = 53) 68 without were analyzed for total its ratio D to L stereoisomers by mass spectrometry. measured molecular markers MRD (WT1 NPM1)...
STAT3 protein phosphorylation is a frequent event in various hematologic malignancies and solid tumors. Acquired mutations have been recently identified 40% of patients with T-cell large granular lymphocytic leukemia, rare disorder. In this study, we investigated the mutational status series lymphoid myeloid diseases. were 1.6% (4 258) neoplasms, 2.5% (2 79) diffuse B-cell lymphoma but no other (0 104) or 96). Functional vitro assays indicated that STAT3Y640F mutation leads to constitutive...
Abstract Aberrant NF-κB activation is a hallmark of most B-cell malignancies. Recurrent inactivating somatic mutations in the NFKBIE gene, which encodes IκBε, an inhibitor NF-κB-inducible activity, are reported several malignancies with highest frequencies chronic lymphocytic leukemia and primary mediastinal lymphoma, account for fraction pathway activation. The impact deficiency on development function remains, however, largely unknown. Here, we show that Nfkbie -deficient mice exhibit...
SUMMARY Mouse embryonic stem cells (mESCs) and other naïve pluripotent can reverse typical developmental trajectories and, at low frequency, de-differentiate into 2-cell-like (2CLCs) that resemble the mammalian embryo during zygotic genome activation (ZGA). This affords opportunity to reveal molecular principles govern pre-implantation stages of development. We leveraged a multipurpose allele for acute protein depletion efficient immunoprecipitation dissect functions chromatin repressor...
<p>PDF file - 170KB, Early mutations affect genes mutated in various human cancers (addition to the main text).</p>
<p>PDF file - 136KB, Representative flow chart of the sorting procedure.</p>